Selected article for: "acute lung inflammation and lung inflammation"

Title: 2017 ACVIM Forum Research Abstract Program
  • Document date: 2017_6_15
  • ID: ri2w5iby_850
    Snippet: Initial assessment of high dose dipyrone was well tolerated in horses when administered twice daily for 15 days. Neutrophils participate in innate immunity as the first line of host defense against microorganisms. However, exacerbated neutrophil activity can be harmful to surrounding tissues; this is important in a range of diseases, including allergic asthma and chronic obstructive pulmonary disease in humans, and equine asthma. Tamoxifen (TX) i.....
    Document: Initial assessment of high dose dipyrone was well tolerated in horses when administered twice daily for 15 days. Neutrophils participate in innate immunity as the first line of host defense against microorganisms. However, exacerbated neutrophil activity can be harmful to surrounding tissues; this is important in a range of diseases, including allergic asthma and chronic obstructive pulmonary disease in humans, and equine asthma. Tamoxifen (TX) is a non-steroidal estrogen receptor modulator with effects on cell growth and survival. TX has been shown to induce early apoptosis of peripheral blood and bronchoalveolar lavage (BAL) neutrophils from horses with acute lung inflammation (Perez et al., 2016) . Our study group previously showed that neutrophil respiratory burst and IL-8-induced chemotaxis also decrease after treatment with TX, confirming a direct action of the drug on the cell type (Borlone et al., 2017) .

    Search related documents:
    Co phrase search for related documents
    • acute lung inflammation and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute lung inflammation and equine asthma: 1
    • allergic asthma and BAL bronchoalveolar lavage: 1
    • allergic asthma and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • allergic asthma and cell type: 1, 2, 3, 4, 5
    • allergic asthma and disease range: 1
    • BAL bronchoalveolar lavage and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • BAL bronchoalveolar lavage and cell type: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • BAL bronchoalveolar lavage and equine asthma: 1, 2
    • BAL bronchoalveolar lavage peripheral blood and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • BAL bronchoalveolar lavage peripheral blood and cell type: 1
    • bronchoalveolar lavage and cell growth: 1, 2
    • bronchoalveolar lavage and cell type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • bronchoalveolar lavage and disease range: 1, 2
    • bronchoalveolar lavage and equine asthma: 1, 2
    • cell growth and direct action: 1
    • cell growth and disease range: 1
    • cell growth and early apoptosis: 1, 2, 3, 4, 5
    • cell growth and estrogen receptor: 1, 2